CCA
ACIU icon

Catalyst Capital Advisors’s AC Immune ACIU Stock Holding History

Catalyst Capital Advisors’s Portfolio ACIU Stock Details ACIU Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-283
Closed -$4K – 491
2016
Q4 		$4K Hold
283
– – ﹤0.01% 352
2016
Q3 		$5K Buy
+283
New +$4.89K ﹤0.01% 371

Other funds holding ACIU

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
DFO
Duquesne Family Office New York $3.38B AUM 61.92% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
PC
PointState Capital New York $7.9B AUM 42.31% 1-Year Est. Return
JG
Jefferies Group New York $12B AUM 6.2% 1-Year Est. Return
HIM
Hillhouse Investment Management Grand Cayman, Cayman Islands $3.13B AUM 7.29% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return

Catalyst Capital Advisors's ACIU Position: Q1 2017 in Review

Catalyst Capital Advisors sold out of AC Immune (ACIU) in Q1 2017, closing a stake of 283 shares — an estimated $4K sold.

Catalyst Capital Advisors first reported a position in ACIU in Q3 2016 and held it in 2 quarters. The position peaked at $5K in Q3 2016. 18 funds tracked by Wall St. Rank hold ACIU as of Q1 2017.

  • Catalyst Capital Advisors reported no remaining AC Immune position as of Q1 2017 after selling out during the quarter.
  • Catalyst Capital Advisors sold 283 AC Immune shares in Q1 2017, an estimated $4K.
  • Catalyst Capital Advisors first reported a position in AC Immune in Q3 2016 and held it in 2 quarters.
  • Catalyst Capital Advisors's AC Immune position peaked at $5K in Q3 2016.
  • 18 funds tracked by Wall St. Rank held AC Immune as of Q1 2017.

Based on Catalyst Capital Advisors's 13F filing for Q1 2017, filed 9 May 2017.